BYD’s profit fell nearly 30% in Q2, its first decline in three years.BYD’s profit fell nearly 30% in Q2, its first decline in three years.

BYD battles price wars locally while accelerating global expansion

BYD, China’s biggest electric vehicle manufacturer, reported its first quarterly profit decline in three years. Second-quarter net income tumbled nearly 30% to ¥6.36 billion ($892 million), coming in well below analyst forecasts.

The Shenzhen-based automaker has been expanding rapidly at home and overseas since 2021, but slowing margins have started to weigh on earnings. While revenue climbed 14% year-over-year to ¥201 billion, the gains weren’t enough to offset the pressure from price cuts. Gross margin slipped to about 18%, down from 18.8% a year earlier, underscoring how discounting is eroding profitability.

BYD battles at home with price wars while accelerating global expansion

China remains the world’s largest electric vehicle market, but the competition has grown cutthroat. Giants like BYD, Tesla, Geely, Nio, and Xpeng are locked in a price war, alongside dozens of smaller brands. To stay competitive, BYD slashed prices on more than 20 models this year, with discounts reaching up to 34%.

The strategy boosted sales volumes but squeezed profits, while excess inventory across the industry pushed automakers to cut prices even further. The relentless race to the bottom has already forced some smaller EV startups out of business.

Regulators have started to intervene. In July, Chinese authorities urged automakers to end what they called “involution”,  a destructive cycle where everyone loses. Officials warned that unchecked price wars risk damaging the supply chain and undermining the global reputation of Chinese-made EVs.

Even BYD, which had a hand in starting the price war in 2023, now acknowledges that it isn’t a viable long-term business model. Executives said in June that the current discounting melee was not sustainable and threatened lasting harm to the industry.

BYD’s foreign operations are booming even as profits slump at home. In the first seven months of 2025, international sales more than doubled. The company has made big inroads in Europe, Southeast Asia, and Latin America.

In Europe in May, BYD took Tesla’s monthly sales. It is also constructing factories in Hungary and Turkey, and has chartered a fleet of roll-on/roll-off ships to accelerate exports. Brazil has emerged as one of its largest international markets, representing about a third of international sales.

And yet, despite this momentum, foreign growth hasn’t been enough to fully compensate for soft margins in China. Analysts say higher marketing expenses and more new technology purchases are dragging down profits.

Growth stalls as financial pains worsen

BYD is also confronting expanding financial burdens. And its working capital deficiency increased from ¥95.8 billion as of March to ¥122.7 billion as of June 30. Its ratio of debt to assets rose to 71.1%.

At the same time, the company has had to rethink how it manages payments to suppliers while continuing to offer steep discounts on inventory. Previously, BYD often delayed payments for more than 200 days, far longer than global industry norms. New government rules now require suppliers to be paid within 60 days. Although this shift helps protect smaller suppliers, it reduces BYD’s financial flexibility and piles additional pressure on its balance sheet.

Spending on research and development is increasing, too; it’s up over 50% from a year ago. BYD is relying on a heavy investment in batteries, electrification, and smart-car technologies to protect its long-term lead. Higher-margin brands like Yangwang and Fangchengbao might offer better margins, but building them out will take time.

Analysts have trimmed expectations. BYD had targeted to sell 5.5 million vehicles in 2025, but estimates now project 5 – 5.2 million. The company remains the dominant force in China’s EV business and a global front-runner in the same segment.

Analysts at Sanford C. Bernstein described the shrinking margins as “scars of competition.” However, the firm still holds an outperform rating on the stock and touted BYD’s global scale and technological edge.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26